PE38997A1 - TACHYCININE ANTAGONIST - Google Patents
TACHYCININE ANTAGONISTInfo
- Publication number
- PE38997A1 PE38997A1 PE1995286859A PE28685995A PE38997A1 PE 38997 A1 PE38997 A1 PE 38997A1 PE 1995286859 A PE1995286859 A PE 1995286859A PE 28685995 A PE28685995 A PE 28685995A PE 38997 A1 PE38997 A1 PE 38997A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- compound
- formula
- disstituted
- carbamoil
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- -1 2-NAPHTHYL Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE AL COMPUESTO ANALGESICO Y ANTIINFLAMATORIO DE FORMULA I DONDE: R1 ES FENILO MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DE HALOGENO, NITRO, CIANO ENTRE OTROS; n ES CERO O UNO; X1 ES OXIGENO, AZUFRE o =NCN; X2 Y X3 SON CADA UNO INDEPENDIENTEMENTE OXIGENO O AZUFRE; R2 ES HIDROGENO O METILO; R3 ES FENILO, FENILO SUSTITUIDO CON HALO, 2-NAFTILO, ENTRE OTROS; Z ES -N(CH3) o -CH2-; R4 ES FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PIRIDILO; R5 ES HIDROGENO, FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PIRIDILO; TAMBIEN SE REFIERE AL PROCESO DE PRODUCCION QUE COMPRENDE LA REACCION DEL COMPUESTO DE FORMULA II DONDE R2, R3, R4 Y R5 YA SE DEFINIERON, CON EL COMPUESTO DE FORMULA R1`-(CH2)n-N=C=X1 EN LA QUE R1' ES FENILO, MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DEL GRUPO QUE CONSISTE DE HALOGENO, NITRO, CIANO ENTRE OTROS; n Y X1 TIENEN LOS SIGNIFICADOS YA INDICADOS; CUANDO SE REQUIERE, LLEVAR A CABO LA DESPROTECCION DEL COMPUESTO ASI OBTENIDO, EN EL QUE R1' ES FENILO SUSTITUIDO POR HIDROXI PROTEGIDO Y/O HIDROXIMETILO PROTEGIDO Y/O REALIZAR LA TRANSFORMACION DEL COMPUESTO ASI OBTENIDO, EN EL QUE R1 ES FENILO SUSTITUIDO POR METOXICARBONILO, PARA OBTENER EL COMPUESTO CORRESPONDIENTE EN EL QUE R1' ES FENILO SUSTITUIDO POR CARBAMOILO o N-METILCARBAMOILO Y LUEGO LA RECUPERACION DEL COMPUESTOIT REFERS TO THE ANALGESIC AND ANTI-INFLAMMATORY COMPOUND OF FORMULA I WHERE: R1 IS MONO PHENYLUS OR DISSTITUTED BY ONE OR TWO SELECTED MEMBERS OF HALOGEN, NITRO, CIANO AMONG OTHERS; n IS ZERO OR ONE; X1 IS OXYGEN, SULFUR, or = NCN; X2 AND X3 ARE EACH INDEPENDENTLY OXYGEN OR SULFUR; R2 IS HYDROGEN OR METHYL; R3 IS PHENYL, PHENYL SUBSTITUTED WITH HALO, 2-NAPHTHYL, AMONG OTHERS; Z IS -N (CH3) or -CH2-; R4 IS PHENYL, 3,5-BIS (TRIFLUOROMETHYL) PHENYL OR PIRIDYL; R5 IS HYDROGEN, PHENYL, 3,5-BIS (TRIFLUOROMETIL) PHENYL OR PIRIDYL; IT ALSO REFERS TO THE PRODUCTION PROCESS THAT INCLUDES THE REACTION OF THE COMPOUND OF FORMULA II WHERE R2, R3, R4 AND R5 HAVE ALREADY BEEN DEFINED, WITH THE COMPOUND OF FORMULA R1`- (CH2) nN = C = X1 WHERE R1 'IS FENILE, MONKEY OR DISSTITUTED BY ONE OR TWO SELECTED MEMBERS OF THE GROUP THAT CONSISTS OF HALOGEN, NITRO, CIANO AMONG OTHERS; n AND X1 HAVE THE MEANINGS ALREADY INDICATED; WHEN REQUIRED, CARRY OUT THE DEPROTECTION OF THE COMPOUND SO OBTAINED, IN WHICH R1 'IS PHENYL SUBSTITUTED FOR PROTECTED HYDROXY AND / OR HYDROXYMETHYLUM PROTECTED AND / OR PERFORM THE ESOOIL, ENOIL , TO OBTAIN THE CORRESPONDING COMPOUND IN WHICH R1 'IS PHENYL SUBSTITUTED BY CARBAMOIL OR N-METHYL CARBAMOIL AND THEN RECOVERY OF THE COMPOUND
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
| GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE38997A1 true PE38997A1 (en) | 1997-10-02 |
Family
ID=26306161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1995286859A PE38997A1 (en) | 1994-12-13 | 1995-12-11 | TACHYCININE ANTAGONIST |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0797583A1 (en) |
| JP (1) | JPH10511935A (en) |
| AR (1) | AR001332A1 (en) |
| AU (1) | AU4343796A (en) |
| BR (1) | BR9509997A (en) |
| CA (1) | CA2204130A1 (en) |
| CO (1) | CO4700289A1 (en) |
| CZ (1) | CZ179097A3 (en) |
| FI (1) | FI971685A7 (en) |
| HU (1) | HUT77002A (en) |
| IL (1) | IL116323A0 (en) |
| NO (1) | NO972526D0 (en) |
| PE (1) | PE38997A1 (en) |
| PL (1) | PL320217A1 (en) |
| SK (1) | SK74697A3 (en) |
| TR (1) | TR199501568A2 (en) |
| WO (1) | WO1996018643A1 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| DE69736390T2 (en) * | 1996-10-07 | 2007-07-26 | Merck Sharp & Dohme Ltd., Hoddesdon | CNS PENETRATING NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSIVE AND / OR ANXIOLYTIC |
| JP2002542151A (en) | 1999-02-18 | 2002-12-10 | 科研製薬株式会社 | Novel amide derivatives as growth hormone secretagogues |
| MXPA02004330A (en) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin. |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| KR100821410B1 (en) | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-phenyl substituted tetrahydroisoquinoline and its therapeutic use |
| NZ552397A (en) | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| ES2382814T3 (en) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment |
| KR101594898B1 (en) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| JP4611444B2 (en) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| JP5319518B2 (en) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | Indoledione derivative |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| PE20121172A1 (en) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| RU2660429C2 (en) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Novel compounds that are erk inhibitors |
| RS56680B1 (en) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Compositions and methods for treating cancer |
| KR102196882B1 (en) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH05186498A (en) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | Proline derivative |
-
1995
- 1995-12-11 PE PE1995286859A patent/PE38997A1/en not_active Application Discontinuation
- 1995-12-11 IL IL11632395A patent/IL116323A0/en unknown
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/en unknown
- 1995-12-12 EP EP95942131A patent/EP0797583A1/en not_active Withdrawn
- 1995-12-12 HU HU9701897A patent/HUT77002A/en unknown
- 1995-12-12 CO CO95058767A patent/CO4700289A1/en unknown
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/en not_active Ceased
- 1995-12-12 SK SK746-97A patent/SK74697A3/en unknown
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 JP JP8518261A patent/JPH10511935A/en active Pending
- 1995-12-12 FI FI971685A patent/FI971685A7/en not_active Application Discontinuation
- 1995-12-12 CA CA002204130A patent/CA2204130A1/en not_active Abandoned
- 1995-12-12 PL PL95320217A patent/PL320217A1/en unknown
- 1995-12-12 BR BR9509997A patent/BR9509997A/en not_active Application Discontinuation
- 1995-12-13 AR AR33458995A patent/AR001332A1/en unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/en unknown
-
1997
- 1997-06-03 NO NO972526A patent/NO972526D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0797583A1 (en) | 1997-10-01 |
| AU4343796A (en) | 1996-07-03 |
| WO1996018643A1 (en) | 1996-06-20 |
| FI971685L (en) | 1997-08-13 |
| MX9703957A (en) | 1997-09-30 |
| TR199501568A2 (en) | 1996-07-21 |
| CZ179097A3 (en) | 1997-10-15 |
| FI971685A0 (en) | 1997-04-18 |
| PL320217A1 (en) | 1997-09-15 |
| BR9509997A (en) | 1997-12-30 |
| FI971685A7 (en) | 1997-08-13 |
| IL116323A0 (en) | 1996-03-31 |
| HUT77002A (en) | 1998-03-02 |
| SK74697A3 (en) | 1997-11-05 |
| CO4700289A1 (en) | 1998-12-29 |
| JPH10511935A (en) | 1998-11-17 |
| CA2204130A1 (en) | 1996-06-20 |
| AR001332A1 (en) | 1997-10-22 |
| NO972526L (en) | 1997-06-03 |
| NO972526D0 (en) | 1997-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE38997A1 (en) | TACHYCININE ANTAGONIST | |
| PE52396A1 (en) | NEW COMPOUND THAT CAN MAINTAIN, INCREASE OR RESTORE CELL SENSITIVITY TO THERAPEUTIC OR PROPHYLACTIC AGENTS | |
| DE69100079D1 (en) | NAPHTHALINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
| HUP0301671A2 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use | |
| PT1075259E (en) | NEW FATAL ANALOGS FOR THE TREATMENT OF DIABETES | |
| ES2128629T3 (en) | BENCILPIPERIDINE DERIVATIVES WITH HIGH AFFINITY AT AMINO ACID RECEPTOR LINK POINTS. | |
| DE69722027D1 (en) | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF | |
| AR006720A1 (en) | A COMPOUND DERIVED FROM HETERO-CYCLIC AZAHEXANE, ITS USE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, PROCEDURE FOR PREPARING IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| ZA842185B (en) | New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof | |
| ATE2428T1 (en) | IMIDAZOLGUANIDINES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM. | |
| PE58599A1 (en) | 2-AMINO-6- (4-PHENOXI-2-SUBSTITUTED) -PIRIDINES SUBSTITUTED | |
| NO983493L (en) | New benzimidazole, benzoxazole and benzothiazole compounds, process for their preparation and pharmaceutical compositions containing such | |
| BG102819A (en) | Alkylaminobenzothiazole derivatives | |
| ES2111930T3 (en) | AMP ACID ANTAGONISTS AND TREATMENT PROCEDURES WITH THE HELP OF THESE. | |
| PE120099A1 (en) | NEW 3,4-DIARYLTIAZOLINE-2-ONA OR 2-THIONA DERIVATIVES, THEIR PREPARATION METHODS AND THERAPEUTIC USE | |
| DE3583872D1 (en) | DIHYDROPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHOD FOR THE PRODUCTION OF THESE COMPOSITIONS. | |
| ES2000456A6 (en) | PROCEDURE FOR PREPARING EICOSATRIINOIC ACID DEVIRATES-5,8,11 AND USE OF THESE IN PHARMACEUTICAL AND COSMETIC COMPOSITIONS. | |
| FR2713085B1 (en) | Dye composition containing sulfur p-phenylenediamines and corresponding dyeing processes, new sulfur p-phenylenediamines and process for their preparation. | |
| DE69618050D1 (en) | Substituted benzylthienylpiperazines, their use as medicines and processes for their manufacture | |
| ATE62908T1 (en) | NEW DERIVATIVES OF 4,5-DIHYDRO-OXAZOLES, PROCESS FOR THEIR PRODUCTION AND THEIR USE. | |
| NO873564L (en) | NEW TYRONINE DERIVATIVES. | |
| ATE20066T1 (en) | NEW BASIC SUBSTITUTED 4-PHENYL-4,5,6,7TETRAHYDROTHIENO-(2,3-C)PYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| DE69316392D1 (en) | AZANORADAMANTANE | |
| DE3676378D1 (en) | ISOXAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. | |
| ATE40948T1 (en) | PYRIDYL ALKYL NITRATE COMPOUND, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |